Article Text


P162 Effect of adding propranolol or increased inhaled corticosteroid dose in persistent asthma
  1. WJ Anderson,
  2. PM Short,
  3. PA Williamson,
  4. A Manoharan,
  5. BJ Lipworth
  1. University of Dundee, Dundee, Scotland, UK


Introduction and Objectives Chronic propranolol does not improve airway hyper-responsiveness (AHR) in persistent asthmatics taking medium dose inhaled corticosteroid (ICS), 440µg/day1. We wished to assess for any putative corticosteroid-sparing effect of propranolol added to low dose ICS versus higher dose ICS, on histamine AHR.

Methods We conducted a randomised double-blind placebo-controlled crossover trial in mild-moderate persistent asthmatics. Patients were run-in for 2 weeks on hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) 100µg/day. Patients were then randomised to either: propranolol 80mg/day plus HFA-BDP 100µg/day; or placebo plus HFA-BDP 400µg/day, each for 4 weeks. Propranolol was up-titrated to 80mg/day for the second 2 weeks of treatment. Patients received tiotropium 18µg/day during run-in and both treatments, which was subsequently discontinued 5 days prior to histamine challenge (primary outcome).

Results 16 patients completed, mean: age 38yr; FEV1 86.4%; Histamine PC20 1.39mg/ml; ICS 406µg/day. Histamine PC20 remained unchanged adding propranolol to HFA-BDP100 compared to baseline (HFA-BDP100): 0.17 doubling dilution (dd) difference (95%CI -0.58–0.92), but there was a significant improvement with HFA-BDP400 compared to both baseline 1.05dd (95%CI 0.43–1.66), P = 0.02; and propranolol 0.88dd (95%CI 0.45–1.30), P = 0.006 (Figure 1a). Significant improvements from baseline were observed with HFA-BDP400 for exhaled nitric oxide, blood eosinophils (Figure 1b) and Asthma Quality of Life Questionnaire (AQLQ) symptom score (Figure 1c), but not with propranolol. Salbutamol recovery time post-challenge was partially blunted by propranolol (median prolongation 5min compared to both baseline and HFA-BDP400, P = 0.002). Domiciliary evening FEV1 also fell with propranolol (mean reduction from baseline 0.22L [95%CI 0.10–0.34L], P = 0.012) while Asthma Control Questionnaire (ACQ) showed no significant changes with either treatment compared to baseline.

Conclusions In mild-moderate persistent asthmatics, propranolol produced no additive effects on top of low dose ICS, while further significant improvements in AHR and inflammation were seen with a higher dose of ICS. Propranolol attenuated salbutamol recovery and reduced evening FEV1, but not ACQ or AQLQ.


  1. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomised placebo- controlled trial to evaluate chronic dosing effects of propranolol in asthma. Am J Respir Crit Care Med 2013;187:1308–1314.

Abstract P162 Figure 1 (A)

Histamine provocative concentration causing 20% fall in FEV1. Geometric means with 95% confidence intervals (Cl). (B) Blood eosinophil count. Means with 95% Cl. (C.) Asthma Quality of Life Questionnaire (AQLQ) symptom component score. Means with 95% CI. HFA = hydrofluoroalkane beclometasone dipropionate. Base = post run-in baseline measurements. HFA100 = 100µg/day. HFA400 = 400µg/day. Prop = Propranolol 80mg/day.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.